Promising Objective Response Rates and Progression-Free Survival but Modest Overall Survival in the TAB Study

被引：1
|
作者：
Okano, Naohiro [1 ]
Mizutani, Tomonori [1 ]
Hironaka, Shuichi [1 ]
机构：
[1] Kyorin Univ, Fac Med, Dept Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 14期
关键词：
D O I：
10.1200/JCO.23.02726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    VALUE IN HEALTH, 2012, 15 (07) : A414 - A415
  • [22] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [23] RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M.
    Aissa, F.
    Lachaine, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 350 - 350
  • [24] Improved estimation of overall survival and progression-free survival for state transition modeling
    Wigfield, Peter C.
    Heeg, Bart
    Ouwens, Mario
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (01)
  • [25] Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
    Petrelli, F.
    Barni, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 186 - 192
  • [26] Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas
    Sagberg, Lisa Millgard
    Salvesen, Oyvind
    Jakola, Asgeir Store
    Thurin, Erik
    de Dios, Eddie
    Nawabi, Noah L. A.
    Kilgallon, John L.
    Bernstock, Joshua D.
    Kavouridis, Vasileios K.
    Smith, Timothy R.
    Solheim, Ole
    ACTA ONCOLOGICA, 2024, 63 : 798 - 804
  • [27] Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Guo, Siyuan
    Godolphin, Peter
    Hussain, Maha
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael A.
    Smith, Matthew R.
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nick
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09)
  • [28] Preserving the Sanctity of Overall Survival for Drugs Approved on the Basis of Progression-Free Survival: Tivozanib As a Case Study
    Garnick, Marc B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (30) : 3746 - 3748
  • [29] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [30] IS PROGRESSION-FREE SURVIVAL A GOOD INDICATOR OF OVERALL SURVIVAL FOR PAZOPANIB IN PATIENTS WITH SYNOVIAL SARCOMA?
    Han, J.
    Lee, S.
    Cho, E.
    VALUE IN HEALTH, 2022, 25 (12) : S489 - S490
12345